查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2070500

生物技術市場規模、佔有率、成長、全球產業分析、區域趨勢以及2026年至2034年的預測

Biotechnology Market Size, Share, Growth, Global Industry Analysis, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

生物技術市場的成長要素

全球生物技術市場到2025年達到13,761億美元，預計從2026年的1,4915億美元成長到2034年的4,3,348億美元，預測期內年複合成長率（CAGR）為14.3%。北美地區引領生技市場，到2025年佔據43.34%的市場佔有率，這得益於其在生物製藥研發方面的大力投資、先進的生產能力以及快速的技術創新。

生物技術是利用生物體、生物系統和細胞過程開發用於醫療保健、農業、工業生產和環境永續性發展的產品和技術的領域。基因組學、基因編輯、合成生物學、生物資訊學和細胞療法的突破性進展推動了該行業的快速發展。對生物製藥、個人化醫療和先進診斷的需求不斷成長，加速全球市場的成長。

生技市場的主要驅動力之一是研發投入的不斷成長。生技公司持續將相當一部分收入投入創新，而世界各國政府也透過津貼、資助舉措和戰略政策持續支持生物技術發展。這些投資加速先進治療方法的商業化進程，包括細胞和基因療法、RNA藥物以及再生醫學解決方案。

例如，到2025年，生技研發將占美國企業研發活動總投資7,820億美元的約17%。此外，人工智慧驅動的藥物發現平台大幅縮短研發時間，提高研究效率，並在生物技術的各個應用領域中降低成本。

生物技術市場趨勢

擴大單次使用和靈活製造

生物技術市場最顯著的趨勢之一是單次使用和靈活生產系統的日益普及。這些技術能夠降低污染風險、減少營運成本、縮短生產週期並提高擴充性。根據產業研究顯示，到2024年，約87%的生物製藥生產設施將採用單一使用系統。

2025年3月，Cytiva公司透過推出新型500公升和2000公升單次生物反應器，擴展了其Xcellerex X平台。這將有助於先進療法的生產，並提高生產的柔軟性。

市場促進因素

生物製藥需求不斷成長

由於生物製藥具有更高的療效、標靶性和更好的安全性，因此持續優於傳統的小分子藥物。對單株抗體、重組蛋白、疫苗和先進生物製藥日益成長的需求，正顯著推動生物技術市場的成長。

到2025年，包括 Keytruda、Mounjaro、Dupixent、Skyrizi、Darzalex、Opdivo在內的眾多重磅藥物預計將產生巨額利潤，凸顯了生物技術療法日益成長的重要性。

市場限制因素

高昂的研發成本

儘管生技公司擁有強勁的成長前景，但它們也面臨著高昂研發成本帶來的重大挑戰。開發生物製藥、細胞療法和基因療法需要20億至40億美元的巨額投資，以及10至12年的漫長研發週期。

臨床試驗的高失敗率會進一步增加財務風險並延緩商業化進程。

市場機會

永續和低碳生產技術

向永續製造的轉型為生物技術公司創造了巨大的機會。工業生物技術能夠生產生物基化學品、再生燃料、酵素和環保材料，減少碳排放和資源消耗。

隨著整個產業對精準發酵和再生原料的採用率不斷提高，預計在預測期內將出現顯著的成長機會。

市場挑戰

不同地區法規的複雜性

生技公司在全球各地市場面臨監管要求各異的挑戰。臨床試驗標準、生產驗證要求以及長期安全性監測方面的差異，往往會導致成本增加和產品核可延誤。

基因療法、mRNA平台和先進生技藥品等新興技術需要廣泛的監管審查，這進一步增加了情況的複雜性。

區域分析

北美洲

預計到2025年，北美將引領生技市場，市場規模將達5,965億美元。該地區強大的生物製藥研究基礎設施、先進的製造能力和高額的醫療保健支出是其主導的重要因素。

預計到2026年，美國生技市場規模將達到 6,155億美元，約佔全球銷售額的41.3%。

歐洲

在生物相似藥日益普及、公共資金投入以及生物製藥生產能力不斷擴大的推動下，預計到2026年，歐洲生物製藥市場規模將達到 3,866億美元。

預計到2026年，德國市場規模將達到 791億美元，而英國市場規模預計將達到 864億美元。

亞太地區

預計到2026年，亞太地區的市場規模將達到 2,939億美元，主要得益於臨床試驗活動的活性化、研發投入的提高以及 GMP 生產能力的擴大。

預計到2026年，中國市場規模將達到 883億美元，印度將達到 523億美元，日本將達到 540億美元。

拉丁美洲、中東和非洲

預計2026年，拉丁美洲生物技術市場規模將達到862億美元，而海灣合作理事會（GCC）生物技術市場規模預計將達322億美元。醫療基礎設施的改善和先進療法的普及是推動該地區市場成長的主要因素。

近期產業發展動態包括：Sartorius AG於2026年 1月擴大永續生物製程解決方案；Thermo Fisher Scientific公司於2025年 12月擴大在亞洲的生物製程設計中心；以及Merck KGaA於2025年 9月宣布將在愛爾蘭新建一座過濾製造廠。

目錄

第1章 引言

第2章 執行摘要

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機會
  • 市場趨勢

第4章 主要考察

  • 生物技術領域的技術進步
  • 主要地區主要疾病盛行率（2025年）
  • 主要國家和地區的監管趨勢
  • 新產品發布：依主要公司分類
  • 產業重大發展動態（合併、收購、合作、新產品和服務的推出等）
  • 概述：生物技術市場投資趨勢

第5章 2021-2034年全球生技市場分析、洞察與預測

  • 市場分析、洞察與預測：依技術分類
    • 基因組學和基因分析技術
    • 合成生物學與基因工程技術
    • 基因編輯技術
    • 細胞工程和細胞培養技術
    • 生物製程技術
    • 奈米生物技術
    • 其他
  • 市場分析、洞察與預測：依應用領域分類
    • 生物製藥藥物發現與臨床前研究
    • 細胞和基因治療
    • 分子診斷
    • 工業生物技術
    • RNA療法與核酸藥物
    • 精準醫療和生物標記開發
    • 再生醫學及組織工程
    • 其他
  • 市場分析、洞察與預測：依最終用戶分類
    • 製藥和生物技術公司
    • CRO 和 CDMO
    • 學術和研究機構
    • 其他
  • 分析、洞察與預測：依地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章 北美生技市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章 歐洲生物技術市場分析、洞察與預測（2021-2034年）

  • 國家
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪地那維亞
    • 其他歐洲國家

第8章 亞太生物技術市場分析、洞察與預測（2021-2034年）

  • 國家
    • 中國
    • 日本
    • 印度
    • 東南亞
    • 澳洲
    • 其他亞太國家

第9章 拉丁美洲生物技術市場分析、洞察與預測（2021-2034年）

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第10章 中東和非洲生物技術市場分析、洞察與預測（2021-2034年）

  • 國家
    • GCC
    • 南非
    • 其他中東和非洲國家

第11章 競爭分析

  • 全球市場佔有率分析（2025年）
  • 公司簡介
    • Eli Lilly and Company
    • AbbVie Inc.
    • F. Hoffmann-La Roche Ltd
    • Pfizer Inc.
    • AstraZeneca
    • Amgen Inc.
    • Gilead Sciences, Inc.
    • Vertex Pharmaceuticals Incorporated
    • Moderna, Inc.
    • BioNTech SE
    • Alnylam Pharmaceuticals, Inc.
    • argenx
    • Genmab A/S
    • Insmed Incorporated
    • CELLTRION INC.
Product Code: FBI116041

Growth Factors of biotechnology Market

The global biotechnology market was valued at USD 1,376.1 billion in 2025 and is projected to grow from USD 1,491.5 billion in 2026 to USD 4,334.8 billion by 2034, registering a CAGR of 14.3% during the forecast period. North America dominated the biotechnology market with a 43.34% market share in 2025, supported by strong investments in biopharmaceutical research, advanced manufacturing capabilities, and rapid technological innovation.

Biotechnology involves the use of living organisms, biological systems, and cellular processes to develop products and technologies for healthcare, agriculture, industrial manufacturing, and environmental sustainability. The industry is experiencing rapid expansion due to breakthroughs in genomics, gene editing, synthetic biology, bioinformatics, and cell-based therapies. Increasing demand for biologics, personalized medicine, and advanced diagnostics is accelerating market growth globally.

A major factor driving the biotechnology market is the increasing investment in research and development. Biotechnology companies consistently allocate a significant portion of their revenues to innovation, while governments worldwide continue to support biotechnology through grants, funding initiatives, and strategic policies. These investments are helping accelerate commercialization of advanced therapies, including cell and gene therapies, RNA-based medicines, and regenerative medicine solutions.

For instance, in 2025, biotechnology R&D represented approximately 17% of the USD 782 billion invested by the U.S. business sector in research and development activities. Additionally, AI-powered drug discovery platforms are significantly reducing development timelines, improving research efficiency, and lowering costs across biotechnology applications.

Biotechnology Market Trends

Expansion of Single-Use and Flexible Manufacturing

One of the most significant trends in the biotechnology market is the growing adoption of single-use and flexible manufacturing systems. These technologies reduce contamination risks, lower operational costs, shorten production cycles, and improve scalability. According to industry surveys, single-use systems were utilized in approximately 87% of biopharmaceutical manufacturing facilities in 2024.

In March 2025, Cytiva expanded its Xcellerex X-platform with new 500L and 2,000L single-use bioreactors, supporting advanced therapeutic manufacturing and enhancing production flexibility.

Market Drivers

Rising Demand for Biopharmaceutical Drugs

Biopharmaceutical products continue to gain preference over conventional small-molecule drugs due to their superior efficacy, targeted action, and improved safety profiles. Increasing demand for monoclonal antibodies, recombinant proteins, vaccines, and advanced biologics is significantly driving biotechnology market growth.

Several blockbuster drugs, including Keytruda, Mounjaro, Dupixent, Skyrizi, Darzalex, and Opdivo, generated substantial revenue in 2025, highlighting the growing importance of biotechnology-based therapeutics.

Market Restraints

High Research and Development Costs

Despite strong growth prospects, biotechnology companies face significant challenges related to high R&D expenses. Developing biologics, cell therapies, and gene therapies requires substantial investments, often ranging from USD 2 billion to USD 4 billion, along with lengthy development timelines of 10-12 years.

High failure rates during clinical trials further increase financial risks and can delay commercialization.

Market Opportunities

Sustainable and Low-Carbon Production Technologies

The shift toward sustainable manufacturing is creating significant opportunities for biotechnology companies. Industrial biotechnology enables the production of bio-based chemicals, renewable fuels, enzymes, and environmentally friendly materials that reduce carbon emissions and resource consumption.

Growing adoption of precision fermentation and renewable feedstocks across industries is expected to create substantial growth opportunities throughout the forecast period.

Market Challenges

Regulatory Complexity Across Regions

Biotechnology companies face challenges associated with diverse regulatory requirements across global markets. Differences in clinical trial standards, manufacturing validation requirements, and long-term safety monitoring often increase costs and delay product approvals.

The complexity becomes even greater for emerging technologies such as gene therapy, mRNA platforms, and advanced biologics, which require extensive regulatory scrutiny.

Segment Analysis

By Technology

The bioprocessing technologies segment dominated the market in 2025 due to increasing biologics production, expansion of manufacturing facilities, and strong investments by industry participants.

The genomics & genetic analysis technologies segment is expected to witness substantial growth during the forecast period, driven by advancements in precision medicine and genetic testing.

By Application

The biopharmaceutical discovery & preclinical research segment held the largest market share in 2025 due to increasing R&D expenditures and growing focus on innovative therapeutic development.

The cell & gene therapy segment is anticipated to register the fastest growth through 2034, supported by expanding clinical pipelines and regulatory approvals.

By End User

Pharmaceutical & biotechnology companies dominated the biotechnology market in 2025 and are expected to account for 53.8% of the market in 2026. Rising investments in manufacturing expansion, product development, and advanced therapeutic research continue to support segment growth.

Regional Analysis

North America

North America led the biotechnology market with a valuation of USD 596.5 billion in 2025. Strong biopharmaceutical research infrastructure, advanced manufacturing capabilities, and high healthcare spending contribute to regional dominance.

The U.S. biotechnology market is projected to reach USD 615.5 billion in 2026, accounting for approximately 41.3% of global revenue.

Europe

Europe is expected to reach USD 386.6 billion in 2026, driven by growing biosimilar adoption, public funding support, and expansion of biologics manufacturing capacity.

Germany is projected to reach USD 79.1 billion, while the U.K. market is expected to achieve USD 86.4 billion in 2026.

Asia Pacific

Asia Pacific is projected to reach USD 293.9 billion in 2026, supported by growing clinical trial activity, increasing R&D investments, and expanding GMP manufacturing capacity.

China is expected to generate USD 88.3 billion, India USD 52.3 billion, and Japan USD 54.0 billion in 2026.

Latin America and Middle East & Africa

Latin America is projected to reach USD 86.2 billion in 2026, while the GCC biotechnology market is expected to attain USD 32.2 billion. Improved healthcare infrastructure and increasing access to advanced therapies are supporting regional growth.

Competitive Landscape

The biotechnology market is highly competitive, with leading companies focusing on pipeline expansion, strategic collaborations, acquisitions, and innovative product launches.

Major companies operating in the market include:

  • Eli Lilly and Company
  • AbbVie Inc.
  • F. Hoffmann-La Roche Ltd
  • Pfizer Inc.
  • AstraZeneca
  • Amgen Inc.
  • Gilead Sciences, Inc.
  • Vertex Pharmaceuticals Incorporated
  • Moderna, Inc.
  • BioNTech SE
  • Alnylam Pharmaceuticals, Inc.
  • argenx
  • Genmab A/S
  • Insmed Incorporated
  • CELLTRION INC.

Recent industry developments include Sartorius AG's expansion of sustainable bioprocessing solutions in January 2026, Thermo Fisher Scientific's expansion of bioprocess design centers across Asia in December 2025, and Merck KGaA's new filtration manufacturing facility in Ireland announced in September 2025.

Conclusion

The biotechnology market is entering a period of rapid expansion driven by breakthroughs in genomics, biologics, cell and gene therapy, synthetic biology, and AI-powered drug discovery. The market is expected to increase from USD 1,376.1 billion in 2025 to USD 4,334.8 billion by 2034, reflecting strong long-term growth potential. Rising R&D investments, increasing demand for advanced therapeutics, adoption of sustainable manufacturing technologies, and expanding healthcare applications will continue to shape the future of the biotechnology industry. While regulatory complexities and high development costs remain challenges, continuous innovation and strategic investments are expected to drive substantial opportunities across global markets through 2034.

Segmentation By Technology, Application, End-User, and Region

By Technology * Genomics & Genetic Analysis Technologies

  • Synthetic Biology & Genetic Engineering Technologies
  • Gene Editing Technologies
  • Cell Engineering & Cell Culture Technologies
  • Bioprocessing Technologies
  • Nanobiotechnology
  • Others

By Application * Biopharmaceutical Discovery & Preclinical Research

  • Cell & Gene Therapy
  • Molecular Diagnostics
  • Industrial Biotechnology
  • RNA Therapeutics & Nucleic Acid Medicines
  • Precision Medicine & Biomarker Development
  • Regenerative Medicine & Tissue Engineering
  • Others

By End-User * Pharmaceutical & Biotechnology Companies

  • CROs & CDMOs
  • Academic & Research Institutes
  • Others

By Region * North America (By Technology, Application, End-User, and Country)

    • U.S.
    • Canada
  • Europe (By Technology, Application, End-User, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Technology, Application, End-User, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Technology, Application, End-User, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Technology, Application, End-User, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Technological Advancements in Biotechnology
  • 4.2. Prevalence of Key Diseases, By Key Regions, 2025
  • 4.3. Regulatory Scenario, By Key Countries/Regions
  • 4.4. New Product Launches, By Key Players
  • 4.5. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)
  • 4.6. Overview: Investment Trends in Biotechnology Market

5. Global Biotechnology Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Technology
    • 5.1.1. Genomics & Genetic Analysis Technologies
    • 5.1.2. Synthetic Biology & Genetic Engineering Technologies
    • 5.1.3. Gene Editing Technologies
    • 5.1.4. Cell Engineering & Cell Culture Technologies
    • 5.1.5. Bioprocessing Technologies
    • 5.1.6. Nanobiotechnology
    • 5.1.7. Others
  • 5.2. Market Analysis, Insights and Forecast - By Application
    • 5.2.1. Biopharmaceutical Discovery & Preclinical Research
    • 5.2.2. Cell & Gene Therapy
    • 5.2.3. Molecular Diagnostics
    • 5.2.4. Industrial Biotechnology
    • 5.2.5. RNA Therapeutics & Nucleic Acid Medicines
    • 5.2.6. Precision Medicine & Biomarker Development
    • 5.2.7. Regenerative Medicine & Tissue Engineering
    • 5.2.8. Others
  • 5.3. Market Analysis, Insights and Forecast - By End User
    • 5.3.1. Pharmaceutical and Biotechnology Companies
    • 5.3.2. CROs & CDMOs
    • 5.3.3. Academic & Research Institutions
    • 5.3.4. Others
  • 5.4. Market Analysis, Insights and Forecast - Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Biotechnology Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Technology
    • 6.1.1. Genomics & Genetic Analysis Technologies
    • 6.1.2. Synthetic Biology & Genetic Engineering Technologies
    • 6.1.3. Gene Editing Technologies
    • 6.1.4. Cell Engineering & Cell Culture Technologies
    • 6.1.5. Bioprocessing Technologies
    • 6.1.6. Nanobiotechnology
    • 6.1.7. Others
  • 6.2. Market Analysis, Insights and Forecast - By Application
    • 6.2.1. Biopharmaceutical Discovery & Preclinical Research
    • 6.2.2. Cell & Gene Therapy
    • 6.2.3. Molecular Diagnostics
    • 6.2.4. Industrial Biotechnology
    • 6.2.5. RNA Therapeutics & Nucleic Acid Medicines
    • 6.2.6. Precision Medicine & Biomarker Development
    • 6.2.7. Regenerative Medicine & Tissue Engineering
    • 6.2.8. Other
  • 6.3. Market Analysis, Insights and Forecast - By End User
    • 6.3.1. Pharmaceutical and Biotechnology Companies
    • 6.3.2. CROs & CDMOs
    • 6.3.3. Academic & Research Institutions
    • 6.3.4. Others
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Biotechnology Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Technology
    • 7.1.1. Genomics & Genetic Analysis Technologies
    • 7.1.2. Synthetic Biology & Genetic Engineering Technologies
    • 7.1.3. Gene Editing Technologies
    • 7.1.4. Cell Engineering & Cell Culture Technologies
    • 7.1.5. Bioprocessing Technologies
    • 7.1.6. Nanobiotechnology
    • 7.1.7. Others
  • 7.2. Market Analysis, Insights and Forecast - By Application
    • 7.2.1. Biopharmaceutical Discovery & Preclinical Research
    • 7.2.2. Cell & Gene Therapy
    • 7.2.3. Molecular Diagnostics
    • 7.2.4. Industrial Biotechnology
    • 7.2.5. RNA Therapeutics & Nucleic Acid Medicines
    • 7.2.6. Precision Medicine & Biomarker Development
    • 7.2.7. Regenerative Medicine & Tissue Engineering
    • 7.2.8. Other
  • 7.3. Market Analysis, Insights and Forecast - By End User
    • 7.3.1. Pharmaceutical and Biotechnology Companies
    • 7.3.2. CROs & CDMOs
    • 7.3.3. Academic & Research Institutions
    • 7.3.4. Others
  • 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Italy
    • 7.4.5. Spain
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Biotechnology Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Technology
    • 8.1.1. Genomics & Genetic Analysis Technologies
    • 8.1.2. Synthetic Biology & Genetic Engineering Technologies
    • 8.1.3. Gene Editing Technologies
    • 8.1.4. Cell Engineering & Cell Culture Technologies
    • 8.1.5. Bioprocessing Technologies
    • 8.1.6. Nanobiotechnology
    • 8.1.7. Others
  • 8.2. Market Analysis, Insights and Forecast - By Application
    • 8.2.1. Biopharmaceutical Discovery & Preclinical Research
    • 8.2.2. Cell & Gene Therapy
    • 8.2.3. Molecular Diagnostics
    • 8.2.4. Industrial Biotechnology
    • 8.2.5. RNA Therapeutics & Nucleic Acid Medicines
    • 8.2.6. Precision Medicine & Biomarker Development
    • 8.2.7. Regenerative Medicine & Tissue Engineering
    • 8.2.8. Other
  • 8.3. Market Analysis, Insights and Forecast - By End User
    • 8.3.1. Pharmaceutical and Biotechnology Companies
    • 8.3.2. CROs & CDMOs
    • 8.3.3. Academic & Research Institutions
    • 8.3.4. Others
  • 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.4.1. China
    • 8.4.2. Japan
    • 8.4.3. India
    • 8.4.4. Southeast Asia
    • 8.4.5. Australia
    • 8.4.6. Rest of Asia Pacific

9. Latin America Biotechnology Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Technology
    • 9.1.1. Genomics & Genetic Analysis Technologies
    • 9.1.2. Synthetic Biology & Genetic Engineering Technologies
    • 9.1.3. Gene Editing Technologies
    • 9.1.4. Cell Engineering & Cell Culture Technologies
    • 9.1.5. Bioprocessing Technologies
    • 9.1.6. Nanobiotechnology
    • 9.1.7. Others
  • 9.2. Market Analysis, Insights and Forecast - By Application
    • 9.2.1. Biopharmaceutical Discovery & Preclinical Research
    • 9.2.2. Cell & Gene Therapy
    • 9.2.3. Molecular Diagnostics
    • 9.2.4. Industrial Biotechnology
    • 9.2.5. RNA Therapeutics & Nucleic Acid Medicines
    • 9.2.6. Precision Medicine & Biomarker Development
    • 9.2.7. Regenerative Medicine & Tissue Engineering
    • 9.2.8. Other
  • 9.3. Market Analysis, Insights and Forecast - By End User
    • 9.3.1. Pharmaceutical and Biotechnology Companies
    • 9.3.2. CROs & CDMOs
    • 9.3.3. Academic & Research Institutions
    • 9.3.4. Others
  • 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America

10. Middle East & Africa Biotechnology Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Technology
    • 10.1.1. Genomics & Genetic Analysis Technologies
    • 10.1.2. Synthetic Biology & Genetic Engineering Technologies
    • 10.1.3. Gene Editing Technologies
    • 10.1.4. Cell Engineering & Cell Culture Technologies
    • 10.1.5. Bioprocessing Technologies
    • 10.1.6. Nanobiotechnology
    • 10.1.7. Others
  • 10.2. Market Analysis, Insights and Forecast - By Application
    • 10.2.1. Biopharmaceutical Discovery & Preclinical Research
    • 10.2.2. Cell & Gene Therapy
    • 10.2.3. Molecular Diagnostics
    • 10.2.4. Industrial Biotechnology
    • 10.2.5. RNA Therapeutics & Nucleic Acid Medicines
    • 10.2.6. Precision Medicine & Biomarker Development
    • 10.2.7. Regenerative Medicine & Tissue Engineering
    • 10.2.8. Other
  • 10.3. Market Analysis, Insights and Forecast - By End User
    • 10.3.1. Pharmaceutical and Biotechnology Companies
    • 10.3.2. CROs & CDMOs
    • 10.3.3. Academic & Research Institutions
    • 10.3.4. Others
  • 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.4.1. GCC
    • 10.4.2. South Africa
    • 10.4.3. Rest of the Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Eli Lilly and Company
    • 11.2.2. AbbVie Inc.
    • 11.2.3. F. Hoffmann-La Roche Ltd
    • 11.2.4. Pfizer Inc.
    • 11.2.5. AstraZeneca
    • 11.2.6. Amgen Inc.
    • 11.2.7. Gilead Sciences, Inc.
    • 11.2.8. Vertex Pharmaceuticals Incorporated
    • 11.2.9. Moderna, Inc.
    • 11.2.10. BioNTech SE
    • 11.2.11. Alnylam Pharmaceuticals, Inc.
    • 11.2.12. argenx
    • 11.2.13. Genmab A/S
    • 11.2.14. Insmed Incorporated
    • 11.2.15. CELLTRION INC.

List of Tables

  • Figure 1: Global Biotechnology Market Revenue Breakdown (USD billion, %) By Region, 2025 & 2034
  • Figure 2: Global Biotechnology Market Value Share (%), By Technology, 2025 & 2034
  • Figure 3: Global Biotechnology Market Value Share (%), By Application, 2025 & 2034
  • Figure 4: Global Biotechnology Market Value Share (%), By End User, 2025 & 2034
  • Figure 5: Global Biotechnology Market Value Share (%), By Region, 2025 & 2034
  • Figure 6: North America Biotechnology Market Value (USD billion), By Technology, 2025 & 2034
  • Figure 7: North America Biotechnology Market Value Share (%), By Technology, 2025
  • Figure 8: North America Biotechnology Market Value (USD billion), By Application, 2025 & 2034
  • Figure 9: North America Biotechnology Market Value Share (%), By Application, 2025
  • Figure 10: North America Biotechnology Market Value (USD billion), By End User, 2025 & 2034
  • Figure 11: North America Biotechnology Market Value Share (%), By End User, 2025
  • Figure 12: North America Biotechnology Market Value (USD billion), by Country, 2025 & 2034
  • Figure 13: North America Biotechnology Market Value Share (%), by Country, 2025
  • Figure 14: Europe Biotechnology Market Value (USD billion), By Technology, 2025 & 2034
  • Figure 15: Europe Biotechnology Market Value Share (%), By Technology, 2025
  • Figure 16: Europe Biotechnology Market Value (USD billion), By Application, 2025 & 2034
  • Figure 17: Europe Biotechnology Market Value Share (%), By Application, 2025
  • Figure 18: Europe Biotechnology Market Value (USD billion), By End User, 2025 & 2034
  • Figure 19: Europe Biotechnology Market Value Share (%), By End User, 2025
  • Figure 20: Europe Biotechnology Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 21: Europe Biotechnology Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 22: Asia Pacific Biotechnology Market Value (USD billion), By Technology, 2025 & 2034
  • Figure 23: Asia Pacific Biotechnology Market Value Share (%), By Technology, 2025
  • Figure 24: Asia Pacific Biotechnology Market Value (USD billion), By Application, 2025 & 2034
  • Figure 25: Asia Pacific Biotechnology Market Value Share (%), By Application, 2025
  • Figure 26: Asia Pacific Biotechnology Market Value (USD billion), By End User, 2025 & 2034
  • Figure 27: Asia Pacific Biotechnology Market Value Share (%), By End User, 2025
  • Figure 28: Asia Pacific Biotechnology Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 29: Asia Pacific Biotechnology Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 30: Latin America Biotechnology Market Value (USD billion), By Technology, 2025 & 2034
  • Figure 31: Latin America Biotechnology Market Value Share (%), By Technology, 2025
  • Figure 32: Latin America Biotechnology Market Value (USD billion), By Application, 2025 & 2034
  • Figure 33: Latin America Biotechnology Market Value Share (%), By Application, 2025
  • Figure 34: Latin America Biotechnology Market Value (USD billion), By End User, 2025 & 2034
  • Figure 35: Latin America Biotechnology Market Value Share (%), By End User, 2025
  • Figure 36: Latin America Biotechnology Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 37: Latin America Biotechnology Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 38: Middle East & Africa Biotechnology Market Value (USD billion), By Technology, 2025 & 2034
  • Figure 39: Middle East & Africa Biotechnology Market Value Share (%), By Technology, 2025
  • Figure 40: Middle East & Africa Biotechnology Market Value (USD billion), By Application, 2025 & 2034
  • Figure 41: Middle East & Africa Biotechnology Market Value Share (%), By Application, 2025
  • Figure 42: Middle East & Africa Biotechnology Market Value (USD billion), By End User, 2025 & 2034
  • Figure 43: Middle East & Africa Biotechnology Market Value Share (%), By End User, 2025
  • Figure 44: Middle East & Africa Biotechnology Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 45: Middle East & Africa Biotechnology Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 46: Global Biotechnology Market Share (%), by Company, 2025